While there are few reports on CTCs as biomarkers for immunotherapy in HCC, a study involving 124 cases receiving immune therapy combined with targeted therapy found that cases with PD-L1 (+) CTCs had extended PFS (HR = 6.359) and OS (HR = 6.67) [68]. Here, CD274 is linked to hepatocellular carcinoma.